Jiangxi Dasheng Pharmaceutical Technology Co., Ltd

Primary Study Objective: This trial used oseltamivir phosphate capsules (75 mg) manufactured by Jiangxi Dasheng Pharmaceutical Technology Co., Ltd. as the test formulation and oseltamivir phosphate capsules (75 mg, trade name: Tamiflu®) manufactured by Delpharm Milano S.r.l. under license from Roche Pharma (Schweiz) AG as the reference formulation. The pharmacokinetic parameters of the test and reference formulations were evaluated in healthy volunteers under both fasting and fed conditions to assess their bioequivalence. Secondary Study Objective: To observe the safety of the test and reference formulations in healthy volunteers.

Main purpose: This study used the licensed Nicergoline Tablets (specification: 10 mg) of Jiangxi Dasheng Pharmaceutical Technology Co., Ltd. as the test preparation and the licensed Nicergoline Tablets (trade name: SERMION, specification: 10 mg) of PFIZER ITALIA S.R.L. as the reference preparation for bioequivalence test. Secondary purpose: To observe the safety of the test preparation and the reference preparation in healthy subjects.

The main purpose of the study was to observe the in vivo kinetics of brivaracetam tablets after a single oral administration in healthy Chinese subjects, estimate the corresponding pharmacokinetic parameters, and use the brivaracetam tablets (trade name: BRIVIACT ®) produced by UCB Pharma S.A. as the reference preparation for bioequivalence evaluation. The secondary purpose of the study was to observe the safety of brivaracetam tablets (test preparation) and brivaracetam tablets (trade name: BRIVIACT ®, reference preparation) in healthy humans.